Abstract Introduction: The sensitivity of conventional cytology for the detection of malignant cells in pleural effusion is insufficient. Since survivin is frequently overexpressed in lung cancer, it might play a role in oncogenesis and progression of the tumor.
Introduction
Pleural effusions are common complications of a wide variety of diseases. The initial diagnostic approach includes thoracocentesis and cytological, histological and biochemical examinations [1] . However, the sensitivity of these noninvasive techniques is only 40-70% [2] . The sensitivity of conventional cytology for the detection of malignant cells in pleural effusion is insufficient [3] . Differentiating between malignant pleural effusion (MPE) and non-MPE often has important therapeutic implications [4] .
The limitations in cytology must be overcome by other techniques and markers. Survivin is an inhibitor of programmed cell death, survivin mediates suppression of apoptosis by inhibition of the caspases 3 and 7, the terminal effectors in apoptotic protease cascades [5] . Survivin is expressed in the G2-M phase of the cell cycle and its interaction with the mitotic spindle apparatus has been reported to be essential for antiapoptotic function [6] . The survivin promotor was highly active in human tumor cells, but not in normal cells, and upregulated by hypoxia in tumor [7] .
Survivin is up-regulated in most cancers, including lung, breast, esophagus, stomach, colon, pancreas, bladder, uterus, ovary and liver carcinomas, soft tissue sarcomas, and leukemias [8] .
In previous publications, survivin in urine has high specificity and sensitivity for diagnosing bladder cancer [9] . Since survivin is frequently overexpressed in lung cancer, it might play a role in oncogenesis and progression of the tumor. It inhibits apoptosis and promotes mitosis [10] . Dong et al. [11] reported on survivin detection in sputum samples and pleural effusions as a new diagnostic approach for lung cancer.
Aim of the work
This study aimed to evaluate diagnostic value of survivin mRNA expression in pleural effusions from lung cancer patients.
Patients and methods
This work was carried out on 85 patients with pleural effusion attended in Chest and Clinical Oncology Departments, Tanta University Hospital during the period from October 2009 to January 2011. This study was performed in compliance with ethical rules at our locality.
Patients
Patients with pleural effusion routinely underwent diagnostic thoracocentesis to obtain pleural fluid specimens for cell count; the measurement of total protein, lactate dehydrogenase (LDH) and cytological examination.
The effusions were classified as benign or malignant according to clinical and pathological diagnoses. Sixty-five pleural fluid specimens were collected from patients with newly diagnosed lung cancer (group I). Twenty benign pleural fluid specimens were also collected (group II), considered to be control group, and this group was classified into transudate and exudate according to Light's criteria [12] .
Malignant pleural effusion was diagnosed if malignant cells were found on cytological examination. Paramalignant effusions were exudative effusions that are not the direct result of neoplastic involvement of the pleura but related to the primary tumor.
Parapneumonic effusions were associated with an acute febrile illness and cough. Chest radiograph revealing pulmonary infiltrates with response to antibiotic treatment. A diagnosis of congestive heart failure (CHF) was made by findings of an enlarged heart, peripheral edema and absence of manifestations of malignancy or manifestations associated with an inflammatory process.
Real time-polymerase chain reaction (RT-PCR) was performed to detect survivin mRNA expression in the pleural fluid specimens.
Assessment of survivin gene expression by real time PCR RNA extraction [13] RNA was isolated from the cells using total RNA isolation kit (gentra systems, USA) and cDNA synthesis was performed with a random hexamer from the High-Capacity cDNA Kit (Applied Biosystem, USA) prim RNA samples for reverse transcription (RT) using MultiScribeä reverse transcriptase enzyme. 
The tubes were placed in thermal cycler of the Gene Amp 5700 sequence detector. The PCR conditions were 2 min at 50°C, followed by 45 cycles for 15 s at 95°C, and 1 min at a primer-specific annealing extension temperature (60°C). Experiments were performed in duplicate. Each PCR run included six standards. At the end of the PCR run, this data is analyzed by the GeneAmp 5700 SDS software. Samples of known DNA concentration were run as standards at the same time as unknown samples, so the concentrations of the unknown samples can be determined.
Statistical analysis
Statistical presentation and analysis of the present study was conducted, using the median, standard error, unpaired student t-test, analysis of variance [ANOVA] test, Mann-Whitney or Kruskal-Wallis by SPSS V18. The sensitivity, specificity and accuracy were calculated by using receiver operating characteristic (ROC) analysis.
Results
Real time-polymerase chain reaction (RT-PCR) was performed to detect the survivin mRNA expression in the pleural fluid specimens. The results were compared with their cytological examinations.
Group I (Lung cancer related pleural effusion): It included 65 patients, 25 (38.46%) females and 40 (61.54%) males, the mean value of age was (62.17 ± 5.53) years. They were thirty-eight (58.46%) malignant pleural effusion with positive cytology and twenty-seven patients (41.54%) para-malignant pleural effusion with negative cytology ( Sixty-five pleural fluid specimens from lung cancer patients (group I) were tested for survivin expression by RT-PCR, only 38/65 (58.46%) had positive cytologic examinations, whereas 62/65 (95.38%) were positive for survivin mRNA. Twenty-seven (41.54%) lung cancer patients were negative for cytologic examination and 24 out of these 27 specimens were positive for survivin mRNA expression. Twenty pleural fluid specimens with benign disease were also studied for survivin mRNA expression (group II), only 4/20 tuberculus cases were positive for survivin mRNA expression (20%). The positive survive expression was significantly higher in group I compared to group IIA and IIB (ANOVA = 45.4, p < 0.01) ( Table 1) .
The median value of survivin mRNA was (3.25 · 10 5 ), (0.3) and (0) in group I, IIA and IIB respectively. There was significant statistical difference in the median value of survivin mRNA among studied groups (ANOVA test = 45.4, p < 0.01) ( Table 1 and Fig. 1 ).
There was no statistical difference in pleural effusion WBC, glucose, protein and LDH in the two studied groups (Table 2) .
Cut-off value of survivin mRNA was determined by the maximum sum of sensitivity and specificity, The cut-off value of survivin mRNA for diagnosis of MPE was 5500 (5.5 · 1000). Analysis of the ROC curves for the survivin mRNA expression in the pleural fluid is shown in Fig. 2 . Pleural fluid survivin mRNA had large area under the ROC curve (0.731) suggesting that it was accurate in differentiating neoplastic from benign exudative effusions. The sensitivity, specificity and accuracy were 89.5%, 50%, 73.1% of survivin for diagnosing MPE (Table 3 ). The sensitivity, specificity, and accuracy were 40%, 93.7%, 67.8% of cytology for diagnosing MPE (see Fig. 3 ).
Correlation between pleural effusion survivin and selected univariate parameters
There was significant correlation between survivin mRNA expression and cytology, stage of the tumor, histological subtype and ECOG performance status (p < 0.05), while no significant correlation was found between age, sex and survivin expression (p > 0.05) ( Table 4) .
Discussion
Pleural fluid cytology remains the most specific, relatively sensitive and inexpensive test and should be an investigation of first choice. If the first pleural fluid sample is negative by cytological examination, at least two other samples should be examined for the presence of malignant cells. Pleural biopsy should be attempted at the same time. If both results are negative, tumor markers should then be tested [15] . Survivin is expressed in a vast majority of human cancers [16] and is one of the key factors conferring and maintaining resistance to apoptosis [17] . Some authors studied 64 lung cancer patients who show a significant up-regulation of survivin mRNA gene expression in tumors. Consistent with that finding, some studies described a strong survivin mRNA up-regulation in NSCLC [10, 18] . There are few reports on survivin expression in pleural effusions of cancer patients [19, 20] . Some investigators stated that survivin is highly up-regulated in malignancy and is involved in the critical determinants of tumor progression such as evasion of apoptosis, increased proliferation and angiogenesis, it is an attractive target for new anti-cancer therapies [21] .
In this study, sixty-five pleural fluid specimens from lung cancer patients were tested for survivin mRNA by RT-PCR, only 38/65 (58.46%) had positive cytologic examinations, The positive rate of survivin mRNA expression in maligant pleural effusion (62/65; 95.38%) was much higher than that in the pleural effusion with benign disease (4/20; 20%, P < 0.01). Twenty-seven cancer patients were negative for cytologic examination and 24/27 were positive for survivin mRNA expression. The sensitivity, specificity and accuracy were 89.5%, 50% and 73.1% of survivin for diagnosing MPE and for cytology was 40%, 93.7% and 67.8% respectively.
Weikert et al. [22] detected survivin mRNA with bladder cancer. In their study urinary survivin mRNA yielded a sensitivity of 68.6% and a specificity of 100% for non-invasive bladder cancer, while urine cytology only gave a sensitivity of 31.4% and a specificity of 97.1%.
Falleni et al. [23] quantified mRNA levels of the apoptosis regulating genes; survivin (member of inhibitors of apoptosis), Bcl-2 and Bax (members of the Bcl-2 family). They studied 22 non-neoplastic pleural samples, comprising normal and inflammatory tissue specimens, and 42 pleural malignant mesotheliomas using real-time RT-PCR. Falleni et al. reported significantly increased levels of survivin mRNA in pleural malignant mesotheliomas compared to normal/fibrotic pleural tissues.
Some authors investigated the expression of survivin protein in the malignant pleural effusions with lung adenocarcinoma and 25 benign pleural effusions; the determination of exfoliated cytology in malignant pleural effusions was also set as a control. Although they studied the expression of survivin protein by immunocytochemistry and western blot, their results were consistent with our study. They detected that survivin protein expression in the malignant pleural effusions was 81.6%, it was significantly higher than that of pleural effusion cytology (52.1%) and benign effusion (8%) [24] .
In the present study, there was significant correlation between survivin mRNA expression and cytology, stage of the tumor, histological subtype (p < 0.05), while no significant correlation was found between age, sex and survivin mRNA expression (p > 0.05). Span et al. [25] reported that survivin mRNA was not correlated with patient age, nodal status, tumor size, histological grade, and hormone receptor status in a breast cancer study.
In agreement with our findings, Zhang et al. [24] reported that there were no relationship between age, sex and lymph node metastasis or distant metastasis with malignant pleural fluid survivin expression.
Recently, some investigators studied 44 pleural effusion specimens for survivin, CA125 and CEA to investigate the diagnostic value of their combined detection for differentiating benign from malignant pleural effusion and ascites. They concluded that the combined detection of survivin, CEA and CA125 in the ascites or pleural effusion may improve the positive rate of diagnosis of ascites and pleural effusion significantly [26] .
Park and colleagues [27] studied pleural effusion samples which were collected from 67 patients with MPE (58 lung cancers; 9 extrathoracic tumors), and from 68 patients with benign conditions (31 with pneumonia; 37 with tuberculosis). Concentrations of pleural fluid survivin, Cyfra 21-1, and carcinoembryonic antigen (CEA) were measured by enzyme-linked immunosorbent assay. Survivin, Cyfra 21-1, and CEA varied in diagnostic accuracy for differentiating MPE from benign pleural effusion by 67.5%, 68.3%, and 93.4%, respectively. The diagnostic accuracy of survivin in our study was 73.1% which is higher than that of the previous study, this can be explained by different method for assessment of survivin.
In conclusion, the findings of this study suggest that survivin mRNA may be helpful in diagnosing MPE as a useful adjuvant of cytology. Survivin mRNA expression has a significant role in differentiating benign from malignant pleural effusion.
